Drug General Information (ID: DDI7LIZYOF)
  Drug Name Azithromycin Drug Info Ondansetron Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Macrolides Antiemetics
  Structure

 Mechanism of Azithromycin-Ondansetron Interaction (Severity Level: Moderate)
     Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Azithromycin Ondansetron
      Mechanism Prolong QT interval Prolong QT interval
      Key Mechanism Factor 1
Factor Name QT interval
Factor Description Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
      Mechanism Description
  • Increased risk of prolong QT interval by the combination of Azithromycin and Ondansetron 

Recommended Action
      Management Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

References
1 Canadian Pharmacists Association.
2 Cerner Multum, Inc. "Australian Product Information.".
3 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4 Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
5 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
6 Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77. [PMID: 12544377]
7 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".